Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4631-4640 Newer>

The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
The Motley Fool March 5, 2008 Brian Lawler	Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool March 5, 2008 Brian Orelli	FDA (Indirectly) Thwacks Amylin The FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs.
The Motley Fool March 3, 2008 Brian Lawler	Watching Big Pharmas' Investments Investors need to take a look at large drugmakers' balance sheets.
The Motley Fool February 29, 2008 Brian Orelli	RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease?
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool February 29, 2008 Brian Lawler	FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.
The Motley Fool February 29, 2008 Brian Orelli	Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried.
<Older 4631-4640 Newer> Return to current articles.